Stepan V. Sizov
Stepan V. Sizov has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Igor V. Oleichik
Mental Health Research Center
14 shared publications - Petr Alexandrovich Baranov
Mental Health Research Center
5 shared publications - E. B. Rumyantseva
Mental Health Research Center
4 shared publications - Oleg S. Brusov
Mental Health Research Center
3 shared publications - Andrey F. Iznak
Mental Health Research Center, Moscow, Russia
2 shared publications - E. F. Vasilyeva
Mental Health Research Center
2 shared publications
Latest Publications
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
The association between blood enzyme activity in patients with depression and delusional disorders and their response to psychopharmacotherapy
Objective. To identify biochemical parameters correlated with the characteristics of the clinical response to psychopharmacotherapy (PFT) in patients with depressive-delusional states of various nosological origins. Material and methods. This study included 54 patients, aged 18 to 52 years, diagnosed with depression and delusional disorders across various nosological categories (F20.02; F25.1; F31.5 according to ICD-10). Scores were obtained using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HAM-D), both administered before and after PPT. Prior to initiating treatment, the activity of enzymes involved in energy metabolism, glutamate metabolism, and antioxidant/glutathione metabolism in platelets and red blood cells was measured. Results. The patient population was segmented into two distinct diagnostic subgroups: schizophrenia spectrum disorders (SSD; F20.02; F25.1; n=34) and affective spectrum disorders (F31.5; n=21). Biochemical parameters were identified within these subgroups that correlated with reductions in PANSS (redPANSS) and HAM-D scores, as well as with scores on these scales following completion of the PPT (PANSS2). In the subgroup with affective disorders, significant correlations were observed between creatine phosphokinase (CPK) activity and redPANSS-Neg (R=0.47, p=0.02), as well as with PANSS-Neg2 (R=–0.52, p=0.01); glutamate dehydrogenase activity also correlated with PANSS-Pos2 (R=–0.48, p=0.01). In the SSD subgroup, correlations were found between CPK and glutathione S-transferase (GST) activity and redPANSS-Pos (R=0.38 and R=0.44, p<0.03). Furthermore, within two distinct patient clusters (n=29 and n=26) identified by biochemical characteristics, notable correlations were observed: in the larger cluster, the CPK activity correlated with redPANSS-Tot, redPANSS-Pos, redPANSS-Neg, and PANSS-Tot2 (R=0.47, R=0.53, R=0.43, R=–0.47, p<0.02); in the smaller cluster, a correlation was identified between the red blood cell GST activity and redPANSS-Neg (R=0.46, p=0.02). Conclusion. The identified significant correlations between biochemical parameters and the degree of reduction in the total score on psychometric scales after the course of therapy make it possible to use these potential candidates as biomarkers in clinical practice to predict the effectiveness of PFT.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
The association between blood enzyme activity in patients with depression and delusional disorders and their response to psychopharmacotherapy
Objective. To identify biochemical parameters correlated with the characteristics of the clinical response to psychopharmacotherapy (PFT) in patients with depressive-delusional states of various nosological origins. Material and methods. This study included 54 patients, aged 18 to 52 years, diagnosed with depression and delusional disorders across various nosological categories (F20.02; F25.1; F31.5 according to ICD-10). Scores were obtained using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HAM-D), both administered before and after PPT. Prior to initiating treatment, the activity of enzymes involved in energy metabolism, glutamate metabolism, and antioxidant/glutathione metabolism in platelets and red blood cells was measured. Results. The patient population was segmented into two distinct diagnostic subgroups: schizophrenia spectrum disorders (SSD; F20.02; F25.1; n=34) and affective spectrum disorders (F31.5; n=21). Biochemical parameters were identified within these subgroups that correlated with reductions in PANSS (redPANSS) and HAM-D scores, as well as with scores on these scales following completion of the PPT (PANSS2). In the subgroup with affective disorders, significant correlations were observed between creatine phosphokinase (CPK) activity and redPANSS-Neg (R=0.47, p=0.02), as well as with PANSS-Neg2 (R=–0.52, p=0.01); glutamate dehydrogenase activity also correlated with PANSS-Pos2 (R=–0.48, p=0.01). In the SSD subgroup, correlations were found between CPK and glutathione S-transferase (GST) activity and redPANSS-Pos (R=0.38 and R=0.44, p<0.03). Furthermore, within two distinct patient clusters (n=29 and n=26) identified by biochemical characteristics, notable correlations were observed: in the larger cluster, the CPK activity correlated with redPANSS-Tot, redPANSS-Pos, redPANSS-Neg, and PANSS-Tot2 (R=0.47, R=0.53, R=0.43, R=–0.47, p<0.02); in the smaller cluster, a correlation was identified between the red blood cell GST activity and redPANSS-Neg (R=0.46, p=0.02). Conclusion. The identified significant correlations between biochemical parameters and the degree of reduction in the total score on psychometric scales after the course of therapy make it possible to use these potential candidates as biomarkers in clinical practice to predict the effectiveness of PFT.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 75-81
Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic)
Objective. A clinical and psychopathological analysis, nosological differentiation of prolonged and chronic manic and manic-delusional states (PMDS) within the framework of the paroxysmal course of endogenous psychoses, determination of the patterns of their development, diagnostic criteria and prognosis. Material and methods. The study included 76 female patients (average age 37.2±8.3 years) who were hospitalized for endogenous mental illnesses with a paroxysmal course that occurred with the clinical picture of PMDS. The patients were divided into two groups: clinical (n=43) and follow-up (n=33). Clinical-psychopathological, clinical-follow-up, psychometric, statistical methods were used. Results. A clinical and dynamic typology of PMDS has been developed, according to which 2 groups have been identified: «monomorphic» PMDS and «polymorphic» PMDS. «Monomorphic» PMDS included 2 subtypes — «acute» and «chronified» and were characterized by the same clinical picture that remained unchanged throughout, while «polymorphic», which also included 2 subtypes — «developing» and «double mania subtype», were characterized by the variability of clinical picture. «Acute» and «developing» subtypes of PMDS predominantly developed in schizoaffective psychosis and bipolar disorder; the «chronified» subtype and the «double mania» subtype were more often observed within the framework of the schizoaffective variant of paroxysmal-progressive schizophrenia. Conclusion. The clinical and dynamic structure of PMDS is heterogeneous and differs in psychopathological structure, as well as in the level of stability of symptoms and characteristics of its course. The developed clinical typology of PMDS is prognostically significant and provides information about the further dynamics of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 75-81
Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic)
Objective. A clinical and psychopathological analysis, nosological differentiation of prolonged and chronic manic and manic-delusional states (PMDS) within the framework of the paroxysmal course of endogenous psychoses, determination of the patterns of their development, diagnostic criteria and prognosis. Material and methods. The study included 76 female patients (average age 37.2±8.3 years) who were hospitalized for endogenous mental illnesses with a paroxysmal course that occurred with the clinical picture of PMDS. The patients were divided into two groups: clinical (n=43) and follow-up (n=33). Clinical-psychopathological, clinical-follow-up, psychometric, statistical methods were used. Results. A clinical and dynamic typology of PMDS has been developed, according to which 2 groups have been identified: «monomorphic» PMDS and «polymorphic» PMDS. «Monomorphic» PMDS included 2 subtypes — «acute» and «chronified» and were characterized by the same clinical picture that remained unchanged throughout, while «polymorphic», which also included 2 subtypes — «developing» and «double mania subtype», were characterized by the variability of clinical picture. «Acute» and «developing» subtypes of PMDS predominantly developed in schizoaffective psychosis and bipolar disorder; the «chronified» subtype and the «double mania» subtype were more often observed within the framework of the schizoaffective variant of paroxysmal-progressive schizophrenia. Conclusion. The clinical and dynamic structure of PMDS is heterogeneous and differs in psychopathological structure, as well as in the level of stability of symptoms and characteristics of its course. The developed clinical typology of PMDS is prognostically significant and provides information about the further dynamics of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (6) , 120-125
Proinflammatory activity of monocytes and activity of glutathione-dependent enzymes in red blood cells in women with depressive conditions
Objective. To search for possible connections between the anti-inflammatory activity of monocytes (PAM) and the activity of glutathione metabolic enzymes: glutathione reductase (GR) and glutathione-S-transferase (GT) in patients with depressive states (DS) within various mental pathologies, as well as between the studied biological parameters and clinical condition of patients. Material and methods. Sixty-one women, aged 18—56 years, with DC were examined before and after treatment. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depressive Symptom Rating Scale (HDRS-21). The control group included 23 women of the corresponding age without mental pathology. Biological parameters were assessed in the peripheral blood of patients and healthy people. Results. Patients with a high level of PAM compared to the control (p<0.001) (subgroup 1, n=31) and with a low (at the control level) level (subgroup 2, n=30) were identified. In the subgroup 1, the values of GR and GT were significantly lower than in patients of subgroup 2 (p<0.05 and p<0.01, respectively). Negative correlations between the level of PAM before treatment and GR before and after treatment were revealed in patients who responded to treatment (r=–0.67; p=0.0041; r=–0.76; p=0.0001). Conclusion. The results may indicate the inverse relationship between the level of PAM and the activity of GR and GT, which are involved in the pathogenesis of DC, and can also serve as criteria for assessing the response of patients to treatment.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (6) , 120-125
Proinflammatory activity of monocytes and activity of glutathione-dependent enzymes in red blood cells in women with depressive conditions
Objective. To search for possible connections between the anti-inflammatory activity of monocytes (PAM) and the activity of glutathione metabolic enzymes: glutathione reductase (GR) and glutathione-S-transferase (GT) in patients with depressive states (DS) within various mental pathologies, as well as between the studied biological parameters and clinical condition of patients. Material and methods. Sixty-one women, aged 18—56 years, with DC were examined before and after treatment. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depressive Symptom Rating Scale (HDRS-21). The control group included 23 women of the corresponding age without mental pathology. Biological parameters were assessed in the peripheral blood of patients and healthy people. Results. Patients with a high level of PAM compared to the control (p<0.001) (subgroup 1, n=31) and with a low (at the control level) level (subgroup 2, n=30) were identified. In the subgroup 1, the values of GR and GT were significantly lower than in patients of subgroup 2 (p<0.05 and p<0.01, respectively). Negative correlations between the level of PAM before treatment and GR before and after treatment were revealed in patients who responded to treatment (r=–0.67; p=0.0041; r=–0.76; p=0.0001). Conclusion. The results may indicate the inverse relationship between the level of PAM and the activity of GR and GT, which are involved in the pathogenesis of DC, and can also serve as criteria for assessing the response of patients to treatment.
- Open Access
- 30 January 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 21 (7) , 6-13
EEG Dynamics During Treatment of Patients with Polymorphic and Monomorphic Subtypes of Prolonged/Chronic Manic-Delusional States
The aim of the study: was to search for differences in the EEG dynamics during the treatment of patients with polymorphic and monomorphic subtypes of prolonged/chronic manic-delusional states (PMDS). Patients and methods: two groups of female patients aged 18–45 with polymorphic (42 patients) and monomorphic (34 patients) subtypes of PMDS were identifed. In all patients, before and after the course of treatment, a multichannel resting EEG was recorded with the measurement of absolute spectral power in narrow frequency sub-bands. A comparative analysis of quantitative EEG spectral parameters was carried out. Intragroup differences in mean EEG spectral power values before and after treatment were identifed using nonparametric statistical criteria. Methods: clinical-psychopathological, psychometric, neurophysiological, statistical. Results: in the group of patients with polymorphic PMDS, compared to the group of patients with monomorphic PMDS, the EEG slowdown under the influence of treatment was significantly stronger and more generalized (in the form of an increase in the spectral power of the EEG in the delta, theta 1, theta 2 and alpha 1 frequency sub-bands), reflecting a greater strengthening of neurophysiological processes of inhibition, which is associated with an improvement in the clinical condition of patients, especially in relation to manic symptoms. Conclusion: the described differences in the functional organization of brain activity may mediate the features of the clinical picture and therapeutic dynamics of patients with polymorphic and monomorphic subtypes of PMDS.
- 30 January 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 21 (7) , 6-13
Open AccessEEG Dynamics During Treatment of Patients with Polymorphic and Monomorphic Subtypes of Prolonged/Chronic Manic-Delusional States
The aim of the study: was to search for differences in the EEG dynamics during the treatment of patients with polymorphic and monomorphic subtypes of prolonged/chronic manic-delusional states (PMDS). Patients and methods: two groups of female patients aged 18–45 with polymorphic (42 patients) and monomorphic (34 patients) subtypes of PMDS were identifed. In all patients, before and after the course of treatment, a multichannel resting EEG was recorded with the measurement of absolute spectral power in narrow frequency sub-bands. A comparative analysis of quantitative EEG spectral parameters was carried out. Intragroup differences in mean EEG spectral power values before and after treatment were identifed using nonparametric statistical criteria. Methods: clinical-psychopathological, psychometric, neurophysiological, statistical. Results: in the group of patients with polymorphic PMDS, compared to the group of patients with monomorphic PMDS, the EEG slowdown under the influence of treatment was significantly stronger and more generalized (in the form of an increase in the spectral power of the EEG in the delta, theta 1, theta 2 and alpha 1 frequency sub-bands), reflecting a greater strengthening of neurophysiological processes of inhibition, which is associated with an improvement in the clinical condition of patients, especially in relation to manic symptoms. Conclusion: the described differences in the functional organization of brain activity may mediate the features of the clinical picture and therapeutic dynamics of patients with polymorphic and monomorphic subtypes of PMDS.
- 6 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 30-34
EEG features in patients with different subtypes of prolonged and chronic endogenous manic-delusional states
The purpose of the study. Analysis of the features of EEG spectral parameters in patients with polymorphic and monomorphic subtypes of prolonged and chronic endogenous manic-delusional states (PEMDS).Materials and methods. A clinical-neurophysiological study was carried out in 76 female patients with monomorphic (group 1, 34 patients) and polymorphic (group 2, 42 patients) subtypes of PEMDS, identified based on clinical-dynamic analysis.Results. In the group 1, compared with the group 2, there were significantly lower values of the spectral power of the pre-treatment EEG in most EEG leads and frequency sub-bands, which reflect a significant deficit in the brain inhibitory systems. In the group 2, the EEG slowdown (in the delta-frequency sub-band) after treatment course, was significantly more pronounced in the frontal-anterotemporal-central cortical zones of the left hemisphere, reflecting a greater increase of the neurophysiological processes of inhibition in these brain areas under the influence of treatment, which leads to an improvement in the clinical condition of patients.Conclusions. The revealed differences in the brain functional activity organization may mediate the features of the clinical picture and therapeutic response in patients with polymorphic and monomorphic subtypes of PEMDS.
- 6 November 2023
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 30-34
EEG features in patients with different subtypes of prolonged and chronic endogenous manic-delusional states
The purpose of the study. Analysis of the features of EEG spectral parameters in patients with polymorphic and monomorphic subtypes of prolonged and chronic endogenous manic-delusional states (PEMDS).Materials and methods. A clinical-neurophysiological study was carried out in 76 female patients with monomorphic (group 1, 34 patients) and polymorphic (group 2, 42 patients) subtypes of PEMDS, identified based on clinical-dynamic analysis.Results. In the group 1, compared with the group 2, there were significantly lower values of the spectral power of the pre-treatment EEG in most EEG leads and frequency sub-bands, which reflect a significant deficit in the brain inhibitory systems. In the group 2, the EEG slowdown (in the delta-frequency sub-band) after treatment course, was significantly more pronounced in the frontal-anterotemporal-central cortical zones of the left hemisphere, reflecting a greater increase of the neurophysiological processes of inhibition in these brain areas under the influence of treatment, which leads to an improvement in the clinical condition of patients.Conclusions. The revealed differences in the brain functional activity organization may mediate the features of the clinical picture and therapeutic response in patients with polymorphic and monomorphic subtypes of PEMDS.
- 1 September 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (8) , 82-89
Features of the neurocognitive profile of patients with protracted and chronic endogenous manic and manic-delusional states
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение нейрокогнитивного профиля больных с затяжными и хроническими эндогенными маниакальными и маниакально-бредовыми состояниями (ЗМС). МАТЕРИАЛ И МЕТОДЫ Обследованы 32 пациентки в возрасте от 18 до 55 лет (средний возраст 36,2±10,2 года) с ЗМС. На основании клинической типологии ЗМС пациентки были разделены на четыре группы по 8 человек в каждой: 1-я группа — «острый» подтип, 2-я — «хронифицированный», 3-я — «развивающийся» и 4-я — подтип «двойной мании». Применялись нейропсихологический, клинико-психопатологический и статистический методы исследования. РЕЗУЛЬТАТЫ Нарушения регуляторно-исполнительных функций и снижение нейродинамических показателей психической деятельности у больных ЗМС были достоверно более выражены, чем в группе контроля (ppU=45,00; pU=30,00; pU=45,00; p<0,001;). Отдельно следует отметить, что выявленные у больных ЗМС когнитивные нарушения не достигали уровня деменции. ЗАКЛЮЧЕНИЕ При ЗСМ наиболее характерными являются когнитивные нарушения, связанные со снижением показателей нейродинамики психической деятельности, относящихся к первому функциональному блоку, а также с дефицитарностью исполнительных функций, нарушением планирования и организации познавательной деятельности, обусловленными слабостью структур третьего функционального блока.
- 1 September 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (8) , 82-89
Features of the neurocognitive profile of patients with protracted and chronic endogenous manic and manic-delusional states
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение нейрокогнитивного профиля больных с затяжными и хроническими эндогенными маниакальными и маниакально-бредовыми состояниями (ЗМС). МАТЕРИАЛ И МЕТОДЫ Обследованы 32 пациентки в возрасте от 18 до 55 лет (средний возраст 36,2±10,2 года) с ЗМС. На основании клинической типологии ЗМС пациентки были разделены на четыре группы по 8 человек в каждой: 1-я группа — «острый» подтип, 2-я — «хронифицированный», 3-я — «развивающийся» и 4-я — подтип «двойной мании». Применялись нейропсихологический, клинико-психопатологический и статистический методы исследования. РЕЗУЛЬТАТЫ Нарушения регуляторно-исполнительных функций и снижение нейродинамических показателей психической деятельности у больных ЗМС были достоверно более выражены, чем в группе контроля (ppU=45,00; pU=30,00; pU=45,00; p<0,001;). Отдельно следует отметить, что выявленные у больных ЗМС когнитивные нарушения не достигали уровня деменции. ЗАКЛЮЧЕНИЕ При ЗСМ наиболее характерными являются когнитивные нарушения, связанные со снижением показателей нейродинамики психической деятельности, относящихся к первому функциональному блоку, а также с дефицитарностью исполнительных функций, нарушением планирования и организации познавательной деятельности, обусловленными слабостью структур третьего функционального блока.
- Open Access
- 30 September 2022
- Published by ECO-Vector LLC in Consortium Psychiatricum
- Vol. 3 (3) , 58-72
Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. METHODS: One hundred sixty eight patients aged 1865 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4th, 7th, 14th, 28th, and 42nd days). RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p 0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.
- 30 September 2022
- Published by ECO-Vector LLC in Consortium Psychiatricum
- Vol. 3 (3) , 58-72
Open AccessClinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. METHODS: One hundred sixty eight patients aged 1865 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4th, 7th, 14th, 28th, and 42nd days). RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p 0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (12) , 138-142
Cinnabarinic acid as a potential prognostic marker of schizophrenia
ЦЕЛЬ ИССЛЕДОВАНИЯ Разработка метода определения циннабариновой кислоты (CA) и ее непосредственного предшественника 3-гидроксиантраниловой кислоты (3HAA) в плазме крови и исследование их концентраций у больных шизофренией до и после лечения. МАТЕРИАЛ И МЕТОДЫ Исследование проводили на выборке из 23 пациентов женского пола с приступообразно-прогредиентным типом течения шизофрении (F20.01). Уровень CA и 3HAA в плазме крови измеряли с помощью метода тандемной хромато-масс-спектрометрии. РЕЗУЛЬТАТЫ Обнаружена обратная статистически значимая корреляция суммы концентраций CA и 3HAA до лечения с суммарным баллом по шкале PANSS после лечения (R=–0,50; p<0,05). Также обнаружена обратная корреляция концентрации CA до лечения с суммарным баллом по шкале PANSS после лечения (R=–0,41, p=0,052), статистически значимая на уровне тренда (0,05<p<0,1). Таким образом, впервые были определены концентрации CA в крови человека. ЗАКЛЮЧЕНИЕ Полученные связи с клиническими данными показывают потенциальную прогностическую значимость определения уровней CA и 3HAA в плазме крови и повышают актуальность дальнейших исследований.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (12) , 138-142
Cinnabarinic acid as a potential prognostic marker of schizophrenia
ЦЕЛЬ ИССЛЕДОВАНИЯ Разработка метода определения циннабариновой кислоты (CA) и ее непосредственного предшественника 3-гидроксиантраниловой кислоты (3HAA) в плазме крови и исследование их концентраций у больных шизофренией до и после лечения. МАТЕРИАЛ И МЕТОДЫ Исследование проводили на выборке из 23 пациентов женского пола с приступообразно-прогредиентным типом течения шизофрении (F20.01). Уровень CA и 3HAA в плазме крови измеряли с помощью метода тандемной хромато-масс-спектрометрии. РЕЗУЛЬТАТЫ Обнаружена обратная статистически значимая корреляция суммы концентраций CA и 3HAA до лечения с суммарным баллом по шкале PANSS после лечения (R=–0,50; p<0,05). Также обнаружена обратная корреляция концентрации CA до лечения с суммарным баллом по шкале PANSS после лечения (R=–0,41, p=0,052), статистически значимая на уровне тренда (0,05<p<0,1). Таким образом, впервые были определены концентрации CA в крови человека. ЗАКЛЮЧЕНИЕ Полученные связи с клиническими данными показывают потенциальную прогностическую значимость определения уровней CA и 3HAA в плазме крови и повышают актуальность дальнейших исследований.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (11) , 131-136
Evaluation of the levels of proinflammatory activity of monocytes in depressed patients with schizophrenia
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить уровень провоспалительной активности моноцитов (ПАМ) у больных с депрессивными состояниями в рамках шизофрении с помощью подсчета количества провоспалительных моноцитов и выявить возможные связи ПАМ с клиническими показателями. МАТЕРИАЛ И МЕТОДЫ Обследованы 68 женщин с депрессивными состояниями в рамках шизофрении и 23 психически и соматически здоровые женщины соответствующего возраста. Клиническое состояние больных оценивали по суммарному баллу шкалы PANSS (PANSS_tot) и шкалы HDRS (HDRS_tot). ПАМ определяли в периферической крови больных и здоровых с помощью подсчета количества больших моноцитов диаметром от 12,5 до 15 мкм на счетчике и анализаторе клеток с использованием для выделения чистой популяции CD14 моноцитов метода позитивной магнитной сепарации. РЕЗУЛЬТАТЫ До лечения у 1/2 обследованных больных уровень ПАМ существенно превышал его значение в контроле (ppr=0,5, ppp=0,06). В подгруппах нонреспондеров подобные закономерности не выявлялись. Обнаруженные закономерности между уровнем ПАМ и выраженностью депрессивных и иных психопатологических расстройств у больных шизофреней могут свидетельствовать об участии иммунного воспаления в патогенезе этого заболевания. ЗАКЛЮЧЕНИЕ Обнаруженная положительная связь между исходно низким уровнем ПАМ и слабой выраженностью депрессивных расстройств может быть использована в качестве прогностического признака ответа больных на лечение.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (11) , 131-136
Evaluation of the levels of proinflammatory activity of monocytes in depressed patients with schizophrenia
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить уровень провоспалительной активности моноцитов (ПАМ) у больных с депрессивными состояниями в рамках шизофрении с помощью подсчета количества провоспалительных моноцитов и выявить возможные связи ПАМ с клиническими показателями. МАТЕРИАЛ И МЕТОДЫ Обследованы 68 женщин с депрессивными состояниями в рамках шизофрении и 23 психически и соматически здоровые женщины соответствующего возраста. Клиническое состояние больных оценивали по суммарному баллу шкалы PANSS (PANSS_tot) и шкалы HDRS (HDRS_tot). ПАМ определяли в периферической крови больных и здоровых с помощью подсчета количества больших моноцитов диаметром от 12,5 до 15 мкм на счетчике и анализаторе клеток с использованием для выделения чистой популяции CD14 моноцитов метода позитивной магнитной сепарации. РЕЗУЛЬТАТЫ До лечения у 1/2 обследованных больных уровень ПАМ существенно превышал его значение в контроле (ppr=0,5, ppp=0,06). В подгруппах нонреспондеров подобные закономерности не выявлялись. Обнаруженные закономерности между уровнем ПАМ и выраженностью депрессивных и иных психопатологических расстройств у больных шизофреней могут свидетельствовать об участии иммунного воспаления в патогенезе этого заболевания. ЗАКЛЮЧЕНИЕ Обнаруженная положительная связь между исходно низким уровнем ПАМ и слабой выраженностью депрессивных расстройств может быть использована в качестве прогностического признака ответа больных на лечение.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (6) , 71-77
Clinical and immunological correlates in endogenous psychoses developed after COVID-19
The clinical and immunological study of the potential impact of coronavirus infection on the course of endogenous psychosis. Thirty-three female patients, aged 16 to 48 years, with depressive-delusional conditions (ICD-10 F20.01, F21, F31) developed after coronavirus infection, of whom 15 people (group 1) had depressive-delusional states 1-2 months after COVID-19 and 18 people (group 2), who developed similar psychoses in later periods (2-6 months). The severity of the psychopathologic symptoms was evaluated with PANSS and HDRS-21 scales. The activity of inflammatory markers - leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) in the blood was determined. The absolute neutrophil count, the absolute lymphocyte count and the neutrophil/lymphocyte ratio were calculated. As a control, we used standard values of indicators of age - and sex-matched healthy donors. The endogenous psychosis that developed later after a coronavirus infection (group 2) is associated with a "typical" inflammatory reaction with an increase in the activity of acute phase proteins (according to α1-PI) and degranulation activity of neutrophils (according to LE), which is associated with the development of depressive-delusional states in patients with the dominance of manifestations of positive affectivity (anxiety, melancholy) and the extended nature of delusional disorders, which were predominantly incongruent to affect. On the contrary, the development of endogenous psychosis during the first two months after COVID-19 (group 1) is characterized by a spectrum of inflammatory biomarkers with a decrease in the number of neutrophils and low activity of LE. This immunological profile is associated with the predominance of manifestations of negative affectivity (apathy, asthenia, adynamia) in the structure of depressive-delusional states and the relatively undeveloped nature of delusional disorders, which were predominantly congruent to affect. The clinical and biological correlates presumably indicate the modulating effect of the coronavirus infection (COVID-19) on neuroinflammation and the structure of endogenous psychosis.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (6) , 71-77
Clinical and immunological correlates in endogenous psychoses developed after COVID-19
The clinical and immunological study of the potential impact of coronavirus infection on the course of endogenous psychosis. Thirty-three female patients, aged 16 to 48 years, with depressive-delusional conditions (ICD-10 F20.01, F21, F31) developed after coronavirus infection, of whom 15 people (group 1) had depressive-delusional states 1-2 months after COVID-19 and 18 people (group 2), who developed similar psychoses in later periods (2-6 months). The severity of the psychopathologic symptoms was evaluated with PANSS and HDRS-21 scales. The activity of inflammatory markers - leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) in the blood was determined. The absolute neutrophil count, the absolute lymphocyte count and the neutrophil/lymphocyte ratio were calculated. As a control, we used standard values of indicators of age - and sex-matched healthy donors. The endogenous psychosis that developed later after a coronavirus infection (group 2) is associated with a "typical" inflammatory reaction with an increase in the activity of acute phase proteins (according to α1-PI) and degranulation activity of neutrophils (according to LE), which is associated with the development of depressive-delusional states in patients with the dominance of manifestations of positive affectivity (anxiety, melancholy) and the extended nature of delusional disorders, which were predominantly incongruent to affect. On the contrary, the development of endogenous psychosis during the first two months after COVID-19 (group 1) is characterized by a spectrum of inflammatory biomarkers with a decrease in the number of neutrophils and low activity of LE. This immunological profile is associated with the predominance of manifestations of negative affectivity (apathy, asthenia, adynamia) in the structure of depressive-delusional states and the relatively undeveloped nature of delusional disorders, which were predominantly congruent to affect. The clinical and biological correlates presumably indicate the modulating effect of the coronavirus infection (COVID-19) on neuroinflammation and the structure of endogenous psychosis.